| Literature DB >> 28520715 |
Thaisa Lucas Sandri1,2, Selorme Adukpo1,3, Dao Phuong Giang4,5, Christian N Nguetse1, Fabiana Antunes Andrade2, Hoang van Tong1,5, Nguyen Linh Toan5,6, Le Huu Song4,5, Preetham Elumalai7, Kumarasamy Thangaraj8, Vijaya Lakshmi Valluri9, Francine Ntoumi10, Christian G Meyer1,5,11, Iara Jose de Messias Reason2, Peter G Kremsner1, Thirumalaisamy P Velavan1,5,10,11.
Abstract
BACKGROUND: Pathogens exert selective pressure which may lead to substantial changes in host immune responses. The human complement receptor type 1 (CR1) is an innate immune recognition glycoprotein that regulates the activation of the complement pathway and removes opsonized immune complexes. CR1 genetic variants in exon 29 have been associated with expression levels, C1q or C3b binding and increased susceptibility to several infectious diseases. Five distinct CR1 nucleotide substitutions determine the Knops blood group phenotypes, namely Kna/b, McCa/b, Sl1/Sl2, Sl4/Sl5 and KCAM+/-.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28520715 PMCID: PMC5435133 DOI: 10.1371/journal.pone.0175973
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Genotypes and allele frequencies of the investigated six CR1 variants among world populations.
| Brazilian | Vietnamese | Indian | Congolese | Ghanaian | |||
|---|---|---|---|---|---|---|---|
| 82 (80) | 99 (100) | 84 (98) | 77 (100) | 77 (100) | < 0.002 | ||
| 20 (20) | 0 | 2 (2) | 0 | 0 | |||
| 0 | 0 | 0 | 0 | 0 | |||
| 184 (90) | 198 (100) | 170 (99) | 154 (100) | 154 (100) | |||
| 20 (10) | 0 | 2 (1) | 0 | 0 | |||
| 98 (96) | 99 (100) | 85 (99) | 77 (100) | 77 (100) | NA | ||
| 4 (4) | 0 | 1 (1) | 0 | 0 | |||
| 0 | 0 | 0 | 0 | 0 | |||
| 200 (98) | 198 (100) | 171 (99) | 154 (100) | 154 (100) | |||
| 4(2) | 0 | 1 (1) | 0 | 0 | |||
| 99 (98) | 99 (100) | 86 (100) | 46 (60) | 35 (45) | <0.0001 | ||
| 2 (2) | 0 | 0 | 27 (35) | 34 (44) | |||
| 0 | 0 | 0 | 4 (5) | 8 (10) | |||
| 200 (99) | 198 (100) | 172 (100) | 119 (77) | 104 (67) | |||
| 2 (1) | 0 | 0 | 35 (23) | 50 (33) | |||
| 94 (93) | 99 (100) | 86 (100) | 7 (9) | 7 (9) | <0.01 | ||
| 7 (7) | 0 | 0 | 31 (40) | 28 (36) | |||
| 0 | 0 | 0 | 39 (51) | 42 (55) | |||
| 195 (96) | 198 (100) | 172 (100) | 45 (29) | 42 (26) | |||
| 7 (4) | 0 | 0 | 109 (71) | 112 (74) | |||
| 99 (98) | 99 (100) | 86 (100) | 77 (100) | 77 (100) | NS | ||
| 2 (2) | 0 | 0 | 0 | 0 | |||
| 0 | 0 | 0 | 0 | 0 | |||
| 200 (99) | 198 (100) | 172 (100) | 154 (100) | 154 (100) | |||
| 2 (1) | 0 | 0 | 0 | 0 | |||
| 61 (60) | 37 (37) | 21 (24) | 0 | 3 (4) | < 0.006 | ||
| 33 (33) | 53 (53) | 39 (46) | 19 (25) | 10 (13) | |||
| 7 (7) | 9 (9) | 26 (30) | 58 (75) | 64 (83) | |||
| 155 (77) | 127 (64) | 81 (47) | 19 (12) | 16 (9) | |||
| 47 (23) | 71 (36) | 91 (53) | 135 (88) | 138 (91) |
NS, not significant; NA, not applicable
Knops blood group antigens distribution among world populations.
| Amino acid substitution | Knops blood antigens | Brazil | Vietnam | India | Congo | Ghana | ||
|---|---|---|---|---|---|---|---|---|
| V1561M | Kna | 200 (98) | 198 (100) | 171 (99.4) | 154 (100) | 154 (100) | NS | |
| Knb | 4 (2) | 0 | 1 (0.6) | 0 | 0 | |||
| K1590E | McCa | 200 (99) | 198 (100) | 172 (100) | 119 (77.3) | 104 (67.5) | <0.0001 | |
| McCb | 2 (1) | 0 | 0 | 35 (22.7) | 50 (32.4) | |||
| R1601G | Sl1 | 195 (96.5) | 198 (100) | 172 (100) | 45 (29.2) | 42 (27.3) | <0.0001 | |
| Sl2 | 7 (3.5) | 0 | 0 | 109 (70.8) | 112 (72.7) | |||
| T1610S | Sl4 | 200 (99) | 198 (100) | 172 (100) | 154 (100) | 154 (100) | NA | |
| Sl5 | 2 (1) | 0 | 0 | 0 | 0 | |||
| I1615V | KCAM+ | 155 (76.7) | 127 (64.1) | 81 (47.1) | 19 (12.3) | 16 (10.4) | <0.0001 | |
| KCAM- | 47 (23.3) | 71 (35.9) | 91 (52.9) | 135 (87.7) | 138 (89.6) |
NS, not significant; NA, not applicable
Reconstructed CR1 haplotype distribution among world populations.
| Brazil | Vietnam | India | Congo | Ghana | ||
|---|---|---|---|---|---|---|
| 130 (64) | 127 (64) | 79 (45.9) | 19 (12.3) | 14 (9) | <0.0005 | |
| 39 (19) | 71 (36) | 90 (52.3) | 26 (17) | 26 (16) | <0.0016 | |
| 19 (9) | 0 | 0 | 0 | 0 | NA | |
| 1 (0.5) | 0 | 0 | 35 (22.7) | 51 (33) | <0.0001 | |
| 3 (1.5) | 0 | 0 | 74 (48) | 63 (41) | <0.0001 | |
| 4 (2) | 0 | 1 (0.6) | 0 | 0 | NS | |
| 1 (0.5) | 0 | 2 (1.2) | 0 | 0 | NS | |
| 2 (1) | 0 | 0 | 0 | 0 | NA | |
| 3 (1.5) | 0 | 0 | 0 | 0 | NA |
NS, not significant; NA, not applicable
Fig 1Distribution of CR1 haplotypes in world populations.
Fig 2Linkage disequilibrium (LD) of CR1 single nucleotide polymorphisms.
LD was calculated based on the data for Brazilian, Indian, Congolese and Ghanaian populations, being the pairwise correlation coefficient values (r2) between tag SNPs referred by numbers inside the squares that show the amount of LD between two SNPs. Black, gray, and white squares represent high, medium and low levels of LD, respectively. Relative position of SNPs on CR1 gene is indicated on the abscissas. (*) Vietnamese population was found monomorphic for five variants except for the variant rs6691117 in CR1 gene, therefore the LD plot for Vietnamese population was not possible.
Significance of CR1 exon 29 Single nucleotide polymorphisms.
| Knops antigens | Amino acid change | Associated outcome | Reference(s) | |
|---|---|---|---|---|
| rs17259045 (4659A>G) | N1540S | Alzheimer disease | [ | |
| rs41274768 (4721G>A) | Kna/b | V1561M | Sickle cell trait | [ |
| rs17047660 (4808A>G) | McCa/b | K1590E | Sickle cell trait | [ |
| Malaria | [ | |||
| Tuberculosis | [ | |||
| Leprosy | [ | |||
| rs17047661 (4841A>G) | Sl1/Sl2 | R1601G | Sickle cell trait | [ |
| Malaria | [ | |||
| Tuberculosis | [ | |||
| rs4844609 (4868T>A) | Sl4/Sl5 | T1610S | Alzheimer disease | [ |
| Cognitive decline | [ | |||
| rs6691117 (4883A>G) | KCAM +/- | I1615V | Erythrocyte Sedimentation Rate | [ |
| Alzheimer Disease | [ | |||
| Gastric cancer | [ | |||
| Lung cancer | [ | |||
| Glioblastoma multiforme | [ | |||
| Preterm birth | [ |